ImmunoAnalysis. 2021;1: 3.
doi: 10.34172/ia.2021.03
  Abstract View: 494
  PDF Download: 276

Original Research

Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells

Khalil Hajiasgharzadeh 1 ORCID logo, Leili Aghebati Maleki 1 ORCID logo, Behzad Baradaran 1, 2* ORCID logo

1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author: Email: baradaranb@tbzmed.ac.ir


Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors. Its biological feature makes it a highly appealing target for cancer treatment. On the other hand, immunotherapy is an efficient approach in cancer treatment, and immunotoxins have a predominant position herein. Thus, this approach can be used in high EGFR-expressed cancer therapy.

Methods: In this study, the production of monoclonal anti-EGFR-recombinant PE38 was used as the special treatment against EGFR-activated cancers. For this purpose, the A431 cell line originating from a squamous carcinoma was used. In order the production of this immunotoxin, the toxin was conjugated with an antibody by chemical method. To confirm conjugation and its purity, SDS-PAGE was performed by immunotoxin electrophoresis. Then, the antitumor effects of immunotoxin in the induction of apoptosis of tumoral cells were assessed by the ELISA method.

Results: The conjugation and purity of immunotoxin were confirmed by immunotoxin electrophoresis. Also, the ELISA results indicate that the produced immunotoxin induced 62% antigen-specific apoptosis (P <0.0001) in tumoral cells compared to the control cells.

Conclusion: To conclude, our study provides a promising therapeutic approach against EGFR-associated cancers and our individual immunotoxin can be used in the treatment of tumors with membranous EGFR.

First Name
Last Name
Email Address
Security code

Abstract View: 494

Your browser does not support the canvas element.

PDF Download: 276

Your browser does not support the canvas element.

Submitted: 02 May 2021
Revision: 06 Jun 2021
Accepted: 12 Jun 2021
ePublished: 13 Jul 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)